Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
18. Dezember 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as...
Ultragenyx anuncia la aprobación de Crysvita® (burosumab) en México para el tratamiento de adultos que viven con hipofosfatemia ligada al cromosoma X (XLH)
11. Dezember 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en el desarrollo de productos novedosos para...
Ultragenyx to Participate at Investor Conferences in November
20. November 2023 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
6th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) --...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17. November 2023 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate in the Jefferies London Healthcare Conference
07. November 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)
06. November 2023 02:00 ET
|
Ultragenyx Pharmaceutical Inc.
ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie...
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
02. November 2023 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to...
Ultragenyx anuncia que Mepsevii® (Vestronidasa alfa) ya está aprobado para su inclusión en el Compendio Nacional de Medicamentos de México para el tratamiento de la Mucopolisacaridosis VII (MPS VII)
01. November 2023 18:34 ET
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una compañía biofarmacéutica dedicada al desarrollo y comercialización de terapias novedosas para...
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
26. Oktober 2023 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
23. Oktober 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...